
PDC*line Pharma

News
New Video following poster presentation at the European Lung Cancer Congress 2025
We are pleased to share a video presentation by Prof. Em Johan Vansteenkiste (University Hospitals Leuven, Belgium), the principal investigator of our clinical trial PDC-LUNG-101 with PDC*lung01, our innovative, "off-the-shelf" therapeutic cancer
PDC*line Pharma Unveils New Clinical Results with PDC*lung01 at the European Lung Cancer Congress 2025
March 23rd 2025, PDC*line Pharma is presenting new results from its ongoing clinical development program at the European Lung Cancer Congress 2025, during the poster session — in the presence of our Principal Investigator, Prof. Johan Vansteenkiste
Publication of a new scientific paper in the peer-reviewed journal "Hepatology Communications"
We’re proud to share our latest research, conducted in collaboration with the Etablissement Français du Sang (EFS), now published in Hepatology Communications! This study showcases the potential of PDC*line, our allogeneic plasmacytoid dendritic cell
PDC*line Pharma presents primary clinical results from phase I/II trial on PDC*lung01 cancer vaccine at ESMO-IO 2024
PDC*line Pharma presents primary clinical results from phase I/II trial on PDC*lung01 cancer vaccine at ESMO-IO 2024
PDC*lung01, in combination with pembrolizumab, demonstrates the potential to provide meaningful clinical benefit compared to
New Article Featuring Our CEO Eric Halioua Published in BioProcess International
We are thrilled to announce that BioProcess International, a leading global platform for the bioprocessing industry, has published a new article featuring an interview with our CEO, Eric Halioua. In this piece, Eric shares the remarkable journey of